Progress in research and development in the medical field is always a good indicator. Hope is bestowed when such advances take place as they signal for better and new ways to deal with diseases. Among such progress is the advent of liposomal formulation in aiding in quicker and better ways of dealing with several ailments.
There has always existed the problem of ingested drugs being digested before reaching their intended target areas in the body. The process of these formulations was discovered as scientists were looking for a solution to this problem. In this solution, the drug would be closed in and protected by a layer of phospholipids and aqueous solution.
The structural composition of the liposomes was adequately suited for the job at hand. It is composed of a mainly liquid core. This is enveloped by a layer of phospholipids, which could be either synthetic or natural. The drugs to be transported, depending on their chemical composition, would either attach to the core or upper layers without being destroyed or denatured.
The main advantage of using liposomes comes from its core structure. The procedure of formation is key to this. They are formed when a specific heat level is exposed to phospholipids immersed in water. This provides the right atmosphere for formation of liposomes. The physiochemical composition should then be deduced so as to enable the liposome act as an appropriate carrier for an appropriate drug - given its composition to avoid any reactions.
When such discoveries are made, researchers are eager to push it so as to find out if the new discovery can lead to better drugs. IN this case it did. An anthracycline drug known as Doxorubicin was developed to help control the spread of cancer. This is achieved by injecting stains of base DNA and RNA into the malignant cells. The enzyme topoisomerase is also injected at a later stage. These procedures inhibit replication of the cells actively controlling their growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
There has been considerable progress in the development of vaccines for diseases which do not have known cures. Such include hepatitis A, which now has a vaccine, Epaxal, under development. Inflexal V is a vaccine developed for several types of influenza especially in children. A vaccine for cancer known as Stimuvax is also in the offering.
The formulation is being investigated on how well it will serve in transportation of dietary supplements to various parts of the body. This testing is inspired by the exceptional success in performance of liposomes in targeted drug delivery. If successful, scientists will use liposomes to transport supplements to various parts of the body where they are required by the body. This procedure has been tried and worked. Therefore, its no longer a risk.
There has always existed the problem of ingested drugs being digested before reaching their intended target areas in the body. The process of these formulations was discovered as scientists were looking for a solution to this problem. In this solution, the drug would be closed in and protected by a layer of phospholipids and aqueous solution.
The structural composition of the liposomes was adequately suited for the job at hand. It is composed of a mainly liquid core. This is enveloped by a layer of phospholipids, which could be either synthetic or natural. The drugs to be transported, depending on their chemical composition, would either attach to the core or upper layers without being destroyed or denatured.
The main advantage of using liposomes comes from its core structure. The procedure of formation is key to this. They are formed when a specific heat level is exposed to phospholipids immersed in water. This provides the right atmosphere for formation of liposomes. The physiochemical composition should then be deduced so as to enable the liposome act as an appropriate carrier for an appropriate drug - given its composition to avoid any reactions.
When such discoveries are made, researchers are eager to push it so as to find out if the new discovery can lead to better drugs. IN this case it did. An anthracycline drug known as Doxorubicin was developed to help control the spread of cancer. This is achieved by injecting stains of base DNA and RNA into the malignant cells. The enzyme topoisomerase is also injected at a later stage. These procedures inhibit replication of the cells actively controlling their growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
There has been considerable progress in the development of vaccines for diseases which do not have known cures. Such include hepatitis A, which now has a vaccine, Epaxal, under development. Inflexal V is a vaccine developed for several types of influenza especially in children. A vaccine for cancer known as Stimuvax is also in the offering.
The formulation is being investigated on how well it will serve in transportation of dietary supplements to various parts of the body. This testing is inspired by the exceptional success in performance of liposomes in targeted drug delivery. If successful, scientists will use liposomes to transport supplements to various parts of the body where they are required by the body. This procedure has been tried and worked. Therefore, its no longer a risk.
No comments:
Post a Comment